Bradykinin induces matrix metalloproteinase-9 expression and cell migration through a PKC-δ-dependent ERK/Elk-1 pathway in astrocytes

GLIA

Volumn 56, Issue 6, 2008, Pages 619-632

  Hsieh, Hsi Lung ^a   Wu, Cheng Ying ^a   Yang, Chuen Mao ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Astrocytes; Bradykinin; Elk 1; MMP 9; PKC

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; GELATINASE B; HISTONE H4; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE C DELTA; PROTEIN P300; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ETS; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE;

ACETYLATION; ANIMAL CELL; ARTICLE; ASTROCYTE; BINDING SITE; CELL MIGRATION; CHROMATIN; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CELL LINE; CELL MOTION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ASTROCYTES; BRADYKININ; BRAIN; CELL LINE, TRANSFORMED; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MATRIX METALLOPROTEINASE 9; PROTEIN KINASE C-DELTA; RATS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 45549092958     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20637     Document Type: Article

References (55)

1. Abbott NJ. 2000. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 20:131-147.
2. Abbott NJ, Rönnbäck L, Hansson E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53.
3. Aoki T, Sumii T, Mori T, Wang X, Lo EH. 2002. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: Mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:2711-2717.
4. Arai K, Lee SR, Lo EH. 2003. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43:254-264.
5. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK. 2004a. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 279:33716-33726.
6. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. 2004b. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/ nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279:51163-51171.
7. Bhoola K, Figueroa C, Worthy K. 1992. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80.
8. Blaukat A, Barac A, Cross MJ, Offermanns S, Dikic I. 2000. G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Gα(q) and Gα(i) signals. Mol Cell Biol 20:6837-6848.
9. Bright JJ. 2007. Curcumin and autoimmune disease. Adv Exp Med Biol 595:425-451.
10. Chan HM, La Thangue NB. 2001. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363-2373.
11. Chen CC, Chang J, Chen WC. 1995. Role of protein kinase C subtypes α and δ in the regulation of bradykinin-stimulated phosphoinositide breakdown in astrocytes. Mol Pharmacol 48:39-47.
12. Cheng CY, Huang CM, Hsiao LD, Sun CC, Jou MJ, Yang CM. 2004. Bradykinin-stimulated p42/p44 MAPK activation associated with cell proliferation in corneal keratocytes. Cell Signal 16:535-549.
13. Cobb MH, Goldsmith EJ. 1995. How MAP kinases are regulated. J Biol Chem 270:14843-14846.
14. Dollery CM, McEwan JR, Henney AM. 1995. Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868.
15. Eberhardt W, Schulze M, Engels C, Klasmeier E, Pfeilschifter J. 2002. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: Involvement of nuclear factor-κB and Ets transcription factors. Mol Endocrinol 16: 1752-1766.
16. El-Dahr SS, Dipp S, Baricos WH. 1998. Bradykinin stimulates the ERK→Elk-1→Fos/AP-1 pathway in mesangial cells. Am J Physiol 275: F343-F352.
17. Ellis EF, Chao J, Heizer ML. 1989. Brain kininogen following experimental brain injury: Evidence for a secondary event. J Neurosurg 71: 437-442.
18. Farina C, Aloisi F, Meinl E. 2007. Astrocytes are active players in cerebral innate immunity. Trends Immunol 28:138-145.
19. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, Shaw PE. 1995. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 14:951-962.
20. Gottschall PE, Yu X. 1995. Cytokines regulate gelatinase A, B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64:1513-1520.
21. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A. 1991. Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Nature 354:531-534.
22. Hsieh HL, Wang HH, Wu CY, Jou MJ, Yen MH, Parker P, Yang CM. 2007. BK-induced cox-2 expression via PKC-S-dependent activation of p42/p44 MAPK and NF-kB in astrocytes. Cell Signal 19:330-340.
23. 2 expression via sequential PKC-δ, p42/p44 MAPK, and NF-κB activation in rat brain astrocytes. J Cell Physiol 206:246-254.
24. Hsieh HL, Yen MH, Jon MJ, Yang CM. 2004. Intracellular signalings underlying bradykinin-induced matrix metalloproteinase-9 expression in rat brain astrocyte-1. Cell Signal 16:1163-1176.
25. Huang C, Jacobson K, Schaller MD. 2004. MAP kinases and cell migration. J Cell Sci 117:4619-4628.
26. Jou TC, Jou MJ, Chen JY, Lee SY. 1985. Properties of rat brain astrocytes in long-term culture. J Formos Med Assoc 84:865-881.
27. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. 1993. The role of bradykinin in mediating ischemic edema in rats. Stroke 24:571-576.
28. Kumari R, Maulik M, Manchanda SC, Maulik SK. 2003. Protective effect of bradykinin antagonist Hoe-140 during in vivo myocardial ischemic-reperfusion injury in the cat. Regul Pept 115:211-218.
29. Lauffenburger DA, Horwitz AF. 1996. Cell migration: A physically integrated molecular process. Cell 84:359-369.
30. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH. 2003. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41:15-24.
31. Li QJ, Yang SH, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M. 2003. MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J 22:281-291.
32. Liebmann C. 2001. Bradykinin signalling to MAP kinase: Cell-specific connections versus principle mitogenic pathways. Biol Chem 382:49-55.
33. Liu JF, Crepin M, Liu JM, Barritault D, Ledoux D. 2002. FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun 293:1174-82.
34. 2+ mobilization in canine cultured tracheal epithelial cells. Br J Pharmacol 126:1341-1350.
35. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L. 2006. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2:169-174.
36. McCawley LJ, Li S, Wattenberg EV, Hudson LG. 1999. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274:4347-4353.
37. Nie M, Pang L, Inoue H, Knox AJ. 2003. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1β in human airway smooth muscle cells: Involvement of different promoter elements, transcription factors, and histone H4 acetylation. Mol Cell Biol 23:9233-9244.
38. Noda M, Sasaki K, Ifuku M, Wada K. 2007. Multifunctional effects of bradykinin on glial cells in relation to potential anti-inflammatory effects. Neurochem Int 51:185-191.
39. Sato H, Seiki M. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395-405.
40. Schwaninger M, Sallmann S, Petersen N, Schneider A, Prinz S, Libermann TA, Spranger M. 1999. Bradykinin induces interleukin-6 expression in astrocytes through activation of nuclear factor-κB. J Neurochem 73:1461-1466.
41. Sgambato V, Vanhoutte P, Pages C, Rogard M, Hipskind R, Besson MJ, Caboche J. 1998. In vivo expression and regulation of Elk-1, a target of the extracellular-regulated kinase signaling pathway, in the adult rat brain. J Neurosci 18:214-226.
42. Sharrocks AD, Brown AL, Ling Y, Yates PR. 1997. The ETS-domain transcription factor family. Int J Biochem Cell Biol 12:1371-1387.
43. Stephens GJ, Cholewinski AJ, Wilkin GP, Djamgoz MB. 1993. Calcium-mobilizing and electrophysiological effects of bradykinin on cortical astrocyte subtypes in culture. Glia 9:269-279.
44. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 9:541-573.
45. Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M. 2002. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem 277:28256-28264.
46. Tiritilli A, El Habach T, Haury L, Duret JF. 2004. BK2 but not BK1 receptors mediating contractile response in human umbilical arteries: Role of thromboxane A2. Methods Find Exp Clin Pharmacol 26:247-252.
47. Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM. 2007. The protein kinase C-η isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene 26:2885-2893.
48. Verkhratsky A, Orkand RK, Kettenmann H. 1998. Glial calcium: Homeostasis and signaling function. Physiol Rev 78:99-141.
49. Wang X, Mori T, Jung JC, Fini ME, Lo EH. 2002. Secretion of matrix metalloproteinase-2 and -9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma 19: 615-625.
50. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, Park JW, Kwon TK. 2004. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK, PKC δ signal transduction. Oncogene 23:1845-1853.
51. Wu CY, Hsieh HL, Jou MJ, Yang CM. 2004. Involvement of p42/p44 MAPK, p38 MAPK, JNK and nuclear factor-κB in interleukin-1β-induced matrix metalloproteinase-9 expression in rat brain astrocytes J Neurochem 90:1477-1488.
52. Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD. 1998. Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J 17:1740-1749.
53. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. 1998. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80.
54. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.
55. Zhang Y, Ye LP, Wang B, Cao SC, Sun LG. 2007. Effect of lead on ERK activity and the protective function of bFGF in rat primary culture astroglia. J Zhejiang Univ Sci B 8:422-427.